Clinical Evidence Handbook

A Publication of BMJ Publishing Group

Constipation in Adults

STEFAN MUELLER-LISSNER, Park-Klinik Weissensee Berlin, Berlin, Germany ARNOLD WALD, University of Wisconsin, Madison, Wisconsin

This is one in a series of chapters excerpted from the Clinical Evidence Handbook, published by the BMJ Publishing Group, London, U.K. The medical information contained herein is the most accurate available at the date of publication. More updated and comprehensive information on this topic may be available in future print editions of the Clinical Evidence Handbook, as well as online at http:// www.clinicalevidence. bmj.com (subscription required). Those who receive a complimentary print copy of the Clinical Evidence Handbook from United Health Foundation can gain complimentary online access by registering on the Web site using the ISBN number of their book.



This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). See CME Quiz on page 901.

A collection of *Clinical Evidence Handbook* published in *AFP* is available at http://www.aafp.org/afp/bmj.

Persons with chronic idiopathic constipation can be divided into two main categories: those with difficulty defecating (but with normal bowel motion frequency) and those with a transit abnormality (which can present as infrequent defecation).

- Although there are defined criteria for the diagnosis of constipation, in practice, diagnostic criteria are less rigid and depend in part on the perception of normal bowel habit.
- Constipation is highly prevalent, with approximately 12 million general practitioner prescriptions for laxatives being written in England in 2001.

Increasing fiber intake and exercise may improve the symptoms and prevalence of constipation.

- We have not found sufficient evidence examining the effects of other nondrug interventions, such as increasing fluid intake or performing biofeedback, although biofeedback may be useful for constipation caused by pelvic floor dyssynergia.
- Despite this lack of firm evidence, a number of poorer-quality studies have shown these lifestyle interventions to be potentially beneficial.

Macrogols (polyethylene glycols) improve symptoms of constipation without serious adverse effects.

- Lactitol and lactulose may be equally effective in improving the frequency of bowel movements.
- We found no randomized controlled trials (RCTs) on the effects of magnesium salts, or phosphate or sodium citrate enemas.

The bulk-forming laxative ispaghula husk (psyllium) seems more effective than lactulose at improving overall symptoms of constipation.

Prucalopride and lubiprostone seem to be more effective than placebo at improving frequency of bowel movements and spontaneous complete bowel movements in persons with chronic constipation.

Although the effectiveness of lubiprostone has been shown in RCTs, we are unsure about its role because of relatively common adverse events.

• We do not know whether other bulkforming laxatives, such as methylcellulose or sterculia, are effective for improving symptoms of constipation.

We do not know the effectiveness of stimulant laxatives, such as bisacodyl, cascara, docusate, glycerol or glycerine suppositories, or senna.

Although generally considered beneficial, we did not find any evidence examining the use of the fecal softeners paraffin and seed oils or arachis oil for treating constipation.

Definition

Bowel habits and perception of bowel habits vary widely within and among populations, making constipation difficult to define. The Rome III criteria is a standardized tool that diagnoses chronic constipation on the basis of two or more of the following symptoms for at least 12 weeks in the preceding six months: straining at defecation on at least one-fourth of occasions, stools that are lumpy or hard on at least one-fourth of occasions, sensation of incomplete evacuation on at least onefourth of occasions, and three or fewer bowel movements per week. In practice, however, diagnostic criteria are less rigid and are partly dependent on perception of normal bowel habit. Typically, chronic constipation is diagnosed when a person has bowel actions twice per week or less for two consecutive weeks, especially in the presence of features such as straining at stool, abdominal discomfort, and sensation of incomplete evacuation.

Clinical Evidence Handbook

Clinical Questions

What are the effects of nondrug interventions in adults with idiopathic chronic constipation?

Likely to be beneficial High-fiber diet or advice to consume a high-fiber diet

Unknown Biofeedback

effectiveness Exercise or advice to exercise

Increasing fluids or advice to increase fluids

What are the effects of fiber supplements in adults with idiopathic chronic constipation?

Likely to be beneficial Ispaghula husk (psyllium)

Unknown Methylcellulose effectiveness Sterculia

What are the effects of paraffin (or similar compounds) in adults with idiopathic chronic constipation?

Unknown Paraffin

effectiveness Seed oils or arachis oil

What are the effects of osmotic laxatives in adults with idiopathic chronic constipation?

Beneficial Macrogols (polyethylene glycols)

Likely to be beneficial Lactitol

Lactulose

Unknown Saline laxatives effectiveness Phosphate enemas

Sodium citrate enemas

What are the effects of stimulant laxatives in adults with idiopathic chronic constipation?

Unknown Bisacodyl effectiveness Cascara

Docusate

Glycerol or glycerin suppositories

Senna

What are the effects of prostaglandin derivatives in persons with idiopathic chronic constipation?

Likely to be beneficial Lubiprostone

What are the effects of 5-hydroxytryptamine 4 receptor agonists in persons with idiopathic chronic constipation?

Likely to be beneficial Prucalopride

Population: For the purposes of this review, we included all RCTs stating that all participants had chronic constipation, whether or not this diagnosis was made according to strict Rome III criteria. Where the definitions of constipation in the RCTs differ markedly from those presented here, we have made this difference explicit. In this review, we deal with chronic constipation not caused by a specific underlying disease (sometimes known as idiopathic constipation) in adults older than 18 years, although we have included adults with pelvic floor dyssynergia. We excluded studies in pregnant women and in persons with constipation associated with underlying specific organic diseases such as dehydration, autonomic neuropathy, spinal cord injury, bowel obstruction, irritable bowel syndrome, or paralytic ileus. We excluded persons with Parkinson disease and dementia, persons who were postoperative, or those who were terminally ill. Persons with opioid-induced constipation were also excluded.

Diagnosis: The diagnosis of constipation is initially based on history. Specific tests available for further investigation include thyroid function tests, calcium concentration, barium enema or colonoscopy, defecation proctography, anorectal manometry, and colon transit time studies.

Incidence and Prevalence

Prevalence data are limited by small samples and problems with definition. One U.K. survey of 731 women found that 8.2 percent had constipation meeting Rome II criteria, and 8.5 percent defined themselves as being constipated. A larger survey (1,892 adults) found that 39 percent of men and 52 percent of women reported straining at stool on more than one-fourth of occasions. Prevalence is increased in older persons. Several surveys from around the world suggest that, in a community setting, prevalence among older persons is about 20 percent.

Etiology and Risk Factors

One systematic review suggests that factors associated with an increased risk of constipation include a low-fiber diet, low fluid intake, reduced mobility, consumption of drugs such as opioids and anticholinergic antidepressants, and Parkinson disease.

Prognosis

Untreated constipation can lead to fecal impaction (with resulting fecal incontinence), particularly in older and confused persons. Constipation has been suggested as a risk factor for hemorrhoids and diverticular disease; however, evidence of causality is lacking.

 $\mbox{\sc editors}$'s note: Prucalopride and sterculia are not available in the United States.

SEARCH DATE: October 2009.

Author disclosure: Stefan Mueller-Lissner has been paid by Axcan Pharma, Boehringer Ingelheim, Menarini Farmaceutica, Movetis NV, Mundipharma GmbH, Pfizer Ltd., Procter & Gamble, Sucampo Pharma, and Zeria Pharma for giving lectures or attending advisory board meetings. Arnold Wald has received consultancy fees from Novartis, Boehringer Ingelheim, and Takeda.

Adapted with permission from Mueller-Lissner S, Wald A. Constipation in adults. *Clin Evid Handbook*. December 2010:164-166. Please visit http://www.clinicalevidence.bmj.com for full text and references. ■